GLP-1 medicines are expanding beyond diabetes and obesity to cardiovascular disease, neurodegeneration, addiction, liver disease, arthritis, and more, with next-generation multi-target peptides in development.
10+ potential indicationsGLP-1 drugs expanding from diabetes and obesity to cardiovascular, neurological, hepatic, autoimmune, and addiction applications
What the researchers found
GLP-1 medicines are expanding from diabetes/obesity to cardiovascular, neurological, hepatic, and autoimmune conditions, with next-generation multi-epitope peptides offering enhanced efficacy through combined hormonal pathway targeting.
Why it matters
GLP-1 drugs may become the most widely prescribed medication class in history. Understanding their expanding indications and evolving drug design is essential for clinicians across specialties.
How the study worked
Narrative review of safety, efficacy, and emerging indications for current and pipeline GLP-1 medicines.
What this study cannot tell us
Many emerging indications are still investigational. Long-term safety of chronic use across diverse populations needs monitoring. Access and cost remain barriers globally.
How to read the evidence
Authoritative narrative review covering established and emerging evidence across multiple therapeutic areas.
When this study was published
Published in 2025, providing a comprehensive current landscape.
The bigger picture
The GLP-1 revolution represents the most significant pharmaceutical development since statins, with potential to reshape treatment across the full spectrum of chronic disease.
Questions still open
- Which emerging indications will gain regulatory approval first?
- How will next-generation multi-target peptides differentiate from current GLP-1 drugs?
- What long-term safety signals should we watch for with chronic GLP-1 use?
Common questions
What can GLP-1 drugs treat beyond diabetes and weight loss?
Are new, better GLP-1 drugs coming?
Read the original research
The expanding landscape of GLP-1 medicines.
Nature medicine, 32(1), 47-57
Citation
Drucker, Daniel J. (2026). The expanding landscape of GLP-1 medicines.. Nature medicine, 32(1), 47-57. https://doi.org/10.1038/s41591-025-04124-5